MARKET

IMUX

IMUX

Immunic Inc
NASDAQ
0.5730
+0.0064
+1.13%
After Hours: 0.5898 +0.0168 +2.93% 17:47 12/19 EST
OPEN
0.5600
PREV CLOSE
0.5666
HIGH
0.5866
LOW
0.5533
VOLUME
2.34M
TURNOVER
--
52 WEEK HIGH
1.390
52 WEEK LOW
0.5533
MARKET CAP
68.92M
P/E (TTM)
-0.6852
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Immunic (IMUX)
TipRanks · 4d ago
Weekly Report: what happened at IMUX last week (1208-1212)?
Weekly Report · 4d ago
Weekly Report: what happened at IMUX last week (1201-1205)?
Weekly Report · 12/08 10:15
Weekly Report: what happened at IMUX last week (1124-1128)?
Weekly Report · 12/01 10:11
Immunic Inc. CEO to Join Evercore ISI Healthcare Conference Fireside Chat
Reuters · 11/26 11:30
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
PR Newswire · 11/26 11:30
Weekly Report: what happened at IMUX last week (1117-1121)?
Weekly Report · 11/24 10:15
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 11/18 21:06
More
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Webull offers Immunic Inc stock information, including NASDAQ: IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.